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BACKGROUND: Women have been associated with higher rates of recurrent events after percutaneous coronary intervention 
than men, possibly attributable to advanced age at presentation and greater comorbidities. These factors also put women at 
higher risk of bleeding, which may influence therapeutic strategies and clinical outcomes.
METHODS AND RESULTS: We performed a patient- level pooled analysis of 4 postapproval registries to evaluate sex- related 
differences in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention. HBR required fulfillment 
of at least 1 major or 2 minor criteria of the Academic Research Consortium definition. Outcomes of interest were major 
bleeding and major adverse cardiac events (composite of cardiac death, myocardial infarction, or definite/probable stent 
thrombosis). Of the total 10 502 patients, 2832 (27.0%) were women. The prevalence of HBR was higher in women com-
pared with men (29.0% versus 20.5%, P<0.0001). Women at HBR were older and had more comorbidities, while men at 
HBR were more often smokers, with prior myocardial infarction and more complex coronary lesions. At 4 years, women at 
HBR had significantly higher major bleeding compared with men at HBR (10.8% versus 6.2%, P<0.0001); however, this dif-
ference was attenuated after multivariable adjustment (hazard ratio, 0.92; 95% CI, 0.41–2.08). Major adverse cardiac event 
rates between groups were similar (12.2% versus 12.6%, P=0.82) and remained consistent after adjustment (hazard ratio, 
0.64; 95% CI, 0.32–1.28).
CONCLUSIONS: The prevalence of HBR was higher in women compared with men, with considerable differences in the distri-
bution of criteria. Women at HBR experienced higher rates of major bleeding but similar major adverse cardiac event rates 
compared with men at HBR at 4 years.
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L
ack of awareness regarding the prevalence of car-
diovascular disease in women makes them less 
likely to undergo diagnostic catheterization and 
subsequent coronary stenting compared with men.1 
In addition, as women are often considered to be at 
higher risk of bleeding after percutaneous coronary in-
tervention (PCI),2,3 they tend to receive a shorter dual 
antiplatelet therapy (DAPT) regimen4 as well as less 
potent antiplatelet agents.5 This conundrum is further 
amplified in women who are considered to be at high 
bleeding risk (HBR) as a result of advanced age or 
multiple comorbid conditions. Concurrently, many of 
the conditions associated with HBR have also been 
identified as risk factors for ischemic events.6 Whether 
this risk perception influences treatment strategies and 
eventually impacts clinical outcomes after PCI differ-
ently in men and women is poorly understood.
Recent randomized trials have demonstrated the 
superiority of certain second- generation drug- eluting 
stents (DES) over bare metal stents in patients at HBR 
undergoing PCI followed by a shortened DAPT dura-
tion.7–9 However, there are currently no available data 
on sex- based long- term outcomes for patients at HBR 
undergoing PCI with second- generation DES in gen-
eral or with the cobalt- chromium everolimus- eluting 
stent (CoCr- EES) specifically.
Therefore, in this study, we aimed to: (1) examine the 
baseline risk profile of patients at HBR undergoing PCI 
according to sex, (2) compare the long- term bleed-
ing and ischemic outcomes by sex in patients at HBR 
undergoing PCI with CoCr- EES implantation, and (3) 
identify the predictors of bleeding and ischemic events 
in men and women at HBR.
METHODS
Study Design and Population
The data that support the findings of this study will not 
be made available to other researchers for purposes 
of reproducing the results or replicating the procedure. 
We pooled patient- level data from 4 postapproval, pro-
spective, open- label, multicenter, single- arm registries 
with up to 4- year follow- ups. These registries were de-
signed to provide further information on the safety pro-
file of the CoCr- EES XIENCE V stent (Abbott Vascular) 
during commercial use in real- world settings in the 
United States (NCT00676520), Japan (NCT01086228), 
India (NCT00631228), and China (NCT01178268), as 
previously detailed.10–12 All studies complied with the 
Declaration of Helsinki and were approved by an in-
stitutional review board at each study site. Only pa-
tients who could provide written informed consent and 
were treated exclusively with CoCr- EES were included. 
There were no protocol- mandated exclusions on the 
basis of clinical descriptors or angiographic criteria. For 
this analysis, only patients at HBR were included from 
the overall pooled database. HBR was defined ac-
cording to the recently published Academic Research 
Consortium for High Bleeding Risk (ARC- HBR) defini-
tion adapted to the variables available in all the stud-
ies.13 Patients were considered to be at HBR if at least 
1 major criterion or 2 minor criteria were met. Major 
ARC- HBR criteria included moderate or severe anemia 
Nonstandard Abbreviations and Acronyms
ARC Academic Research Consortium
CKD chronic kidney disease
CoCr- EES  cobalt- chromium everolimus- eluting 
stent
DAPT dual antiplatelet therapy
DES drug- eluting stent
HBR high bleeding risk
ID- TLR  ischemia- driven target lesion 
revascularization
LVEF left ventricular ejection fraction








• Among patients undergoing percutaneous coro-
nary intervention, the prevalence of high bleed-
ing risk (HBR) was significantly higher in women 
compared with men, with considerable differ-
ences in the distribution of qualifying criteria.
• Women at HBR experienced higher rates of 
major bleeding compared with men at HBR, a 
finding that could be partly ascribed to differing 
baseline clinical conditions.
• Rates of major adverse cardiac events in pa-
tients at HBR were comparable across sexes.
What Are the Clinical Implications?
• The Academic Research Consortium definition 
represents a useful tool for bleeding risk as-
sessment in both men and women undergoing 
percutaneous coronary intervention.
• Sex-related differences in HBR features should 
be taken into consideration when optimizing re-
vascularization strategies and subsequent an-
tithrombotic therapy.
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(hemoglobin <11 g/dL), use of long- term oral antico-
agulation, severe or end- stage chronic kidney disease 
(CKD) (estimated glomerular filtration rate, <30 mL/min), 
thrombocytopenia (platelet count <100×109/L), spon-
taneous bleeding requiring hospitalization or trans-
fusion, and active malignancy. Minor ARC- HBR 
criteria included age 75 years and older, mild anemia 
(hemoglobin 11–12.9  g/dL for men or 11–11.9  g/dL 
for women), moderate CKD (estimated glomerular fil-
tration rate, 30–59 mL/min), and moderate or severe 
stroke >6  months ago. Treatment strategies, includ-
ing stent implantation techniques and periprocedural 
pharmacotherapy, were determined by site- based 
clinical practice. The antithrombotic management for 
all patients was ultimately determined by the treating 
physicians. However, protocol recommendations for 
antiplatelet therapy included an indefinite duration of 
aspirin, along with a required minimum of 6 months of 
P2Y12 inhibitors.
End Point Definitions
The primary end points were major bleeding (MB) and 
major adverse cardiac events (MACE). MB was defined 
according to the Thrombolysis In Myocardial Infarction 
(TIMI) or Global Utilization of Streptokinase and TPA for 
Occluded Coronary Arteries (GUSTO) scales depending 
on the registry, and included bleeding events catego-
rized as TIMI minor or major (Xience V United States and 
Xience V India) or GUSTO moderate or severe (Xience 
V China and Xience V Japan). MACE was defined as 
occurrence of cardiac death, myocardial infarction (MI) 
according to the World Health Organization (WHO) defi-
nition,14 or definite/probable stent thrombosis (ST) ac-
cording to the Academic Research Consortium (ARC) 
definition.15 Other end points of interest were all- cause 
death, cardiac death, MI, ST, and ischemia- driven tar-
get lesion revascularization. End points adjudicated by 
an independent clinical events committee are reported 
in Table S1. To summarize, all cardiac and majority of 
bleeding events were adjudicated. Patients were clini-
cally followed up by either telephone contact or office 
visits at 30 days, 180 days, and 1 year, and then annu-
ally up to 4 years after index PCI. The median duration 
of follow- up for the study patients was 1430 days (inter-
quartile range, 1083–1460).
Statistical Analysis
Continuous variables were reported as mean±SD or 
median±interquartile range and compared using Student 
t test or Wilcoxon rank sum test. Categorical data were 
reported as proportions and compared by chi- square 
test or Fisher exact test. Four- year event rates were es-
timated using Kaplan–Meier time- to- event methodology 
and compared using log- rank test. Independent predic-
tors of MB and MACE were evaluated using stepwise 
Cox proportional hazard regression. Two separate mul-
tivariable models were created for men and women 
at HBR. Variables were entered into the model either 
through clinical judgement or at the 0.05 significance 
level and removed at the 0.05 level (from the Wald chi- 
square statistic). Variables were eligible for inclusion in 
the multivariable model- building process if the variable 
was present for 90% of the patients in the analyses, had 
a univariate P<0.05, and had the higher level of signifi-
cance, if highly correlated with another variable (r>0.5 
and P<0.05). The following variables were included: 
age 75 years and older, history of MB, history of stroke, 
chronic oral anticoagulation, CKD, anemia, thrombocy-
topenia, sex, multivessel disease, diabetes mellitus, cur-
rent smoker, hypertension, hyperlipidemia, acute MI at 
admission, left ventricular ejection fraction <30%, prior 
cardiac intervention, prior MI, minimum reference vessel 
diameter, maximum lesion length, left main lesion, graft 
lesion, B2/C lesion, bifurcation lesion, restenotic lesion, 
ostial lesion, number of lesions treated, number of ves-
sels treated, and number of stents implanted. Results 
are reported as hazard ratios (HRs) with 95% CIs. We 
reported 2- sided P values and considered P<0.05 to be 
significant. All analyses were performed using SAS ver-
sion 9.4 software (SAS Institute Inc).
RESULTS
Baseline and Procedural Characteristics
Of the total 10  502 patients included in this pooled 
analysis, 2832 (27.0%) patients were women and 7670 
(73.0%) patients were men. The prevalence of HBR 
was significantly higher in women compared with 
men (29.0% versus 20.5%, respectively; P<0.0001). 
Baseline and procedural characteristics according to 
sex are detailed in Table 1. Women at HBR were older 
and had more comorbidities such as diabetes mellitus, 
hypertension, and hyperlipidemia. Men at HBR were 
more often active smokers and had a higher preva-
lence of prior MI. With regard to the procedural char-
acteristics, women at HBR were more likely to have a 
smaller reference vessel diameter and shorter lesion 
length, while men at HBR had a higher prevalence of 
B2/C lesions. Comparison of the prevalence of vari-
ous criteria in patients at HBR by sex is illustrated in 
Figure 1. The most common major ARC- HBR criterion 
was moderate/severe anemia in women at HBR and 
use of long- term oral anticoagulation in men at HBR. 
Age 75 years and older and mild anemia were the most 
common minor ARC- HBR criteria in women and men 
at HBR, respectively.
DAPT Management
Comparison of DAPT management between patients 
at HBR and those not at HBR according to sex is 
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illustrated in Figure  2. A total of 75.4% of women at 
HBR were on DAPT 1 year after index procedure, while 
82.3% of women not at HBR were on DAPT at the 
same time point (P<0.0001). At 4 years post-index pro-
cedure, 38.7% of women at HBR and 44.1% of women 
not at HBR were on DAPT (P=0.01).
In men, 77.3% of patients at HBR were on DAPT 
1 year post- PCI compared with 85.0% of patients not 
at HBR (P<0.0001). The percentage of patients on 
DAPT at 4 years post- PCI was also significantly lower 
in men at HBR compared with men not at HBR (37.3% 
versus 45.1%, respectively; P<0.0001).
Tables S2 and S3 compare the DAPT rates be-
tween men and women at HBR and those not at HBR, 
respectively. Within the HBR population, we observed 
comparable DAPT rates between women and men up 
to 4 years. In the non- HBR population, however, DAPT 
rates were significantly lower in women compared with 
men up to 2 years post- PCI, with no significant differ-
ences at 3 and 4 years.
Clinical Outcomes
Long- term clinical outcomes for HBR patients by 
sex are detailed in Table 2 and Figure 3. Women at 
HBR had significantly higher rates of MB at 4  years 
compared with men at HBR (10.8% versus 6.2%, 
P<0.0001; respectively). Rates of 4- year MACE were 
similar between the 2 groups (12.2% versus 12.6%, 
P=0.82; respectively). There were no significant differ-
ences in the incidence of individual end points such as 
all- cause mortality, cardiac death, MI, and ST between 
men and women at HBR. After adjusting for possible 
baseline confounders, the differences in MB were at-
tenuated and no longer significant between men and 
women at HBR (HR, 0.92; 95% CI, 0.41–2.08). The 
findings for MACE remained consistent after multivari-
able adjustment (HR, 0.64; 95% CI, 0.32–1.28).
Table S4 illustrates the sex- wise outcomes in 
patients at HBR up to 3 years. In addition, rates of MB 
in women, men, and the overall non- HBR population 
are reported in Table S5. At 1 year, women not at HBR 
had a 1.8% rate of MB compared with 1.5% for men 
not at HBR. At 4 years, rates of MB were 6.9% and 
4.6% in women and men not at HBR, respectively.
Sex- wise 4- year clinical outcomes in the overall 
population are detailed in Table S6. While the event 
rates in the overall population were much lower than 
in the HBR cohort, the unadjusted and adjusted HRs 
between sexes in the overall study population were 
qualitatively similar to the HBR population.
To evaluate the impact of clinical presentation on 
sex- based long- term outcomes, women and men at 
HBR were further stratified into ST- segment–elevation 
MI and non–ST- segment–elevation acute coronary 
syndrome groups. Outcomes at 4 years are reported 
in Tables S7 and S8 for ST- segment–elevation MI 
and non–ST- segment–elevation acute coronary syn-
drome, respectively. In line with the primary results of 
the analysis, MACE rates were comparable between 
sexes, with numerically higher rates of MB observed in 
women at HBR for both ST- segment–elevation MI and 
Table 1. Clinical and Procedural Characteristics
Women at HBR 
(n=821)
Men at HBR 
(n=1576) P Value
Baseline characteristics
Age, y 72.7±10.5 (821) 70.6±11.0 (1576) <0.0001
Current smoker 9.6% (75/785) 19.5% (295/1515) <0.0001
Diabetes 
mellitus
48.7% (399/820) 42.9% (673/1570) 0.007
Hypertension 89.6% (735/820) 85.1% (1335/1568) 0.002
Hyperlipidemia 79.4% (639/805) 71.0% (1079/1520) <0.0001
LVEF <30% 4.4% (27/608) 4.8% (55/1145) 0.73
Multivessel 
disease
40.7% (334/821) 45.3% (711/1571) 0.03
Prior cardiac 
intervention
48.1% (379/788) 49.1% (741/1510) 0.66
Prior MI 26.7% (198/741) 32.4% (471/1453) 0.006
Clinical 
presentation
Acute MI 17.1% (122/712) 18.6% (267/1434) 0.40
Procedural characteristics
No. of treated 
lesions per 
patient
1.3±0.6 (821) 1.4±0.7 (1576) 0.82
No. of treated 
vessels per 
patient
1.1±0.4 (787) 1.1±0.4 (1483) 0.21
No. of stents 
implanted per 
patient
1.6±0.8 (821) 1.6±0.9 (1576) 0.46
RVD, mm 2.92±0.48 (983) 3.00±0.58 (1896) <0.0001
Lesion length, 
mm
17.1±10.5 (972) 18.7±11.5 (1897) 0.0003
B2/C lesion 55.5% (501/902) 60.0% (1035/1724) 0.03
Left main 2.2% (24/1104) 3.0% (64/2132) 0.17
Graft 3.6% (40/1104) 5.3% (112/2132) 0.04
Restenosis 
lesion
10.8% (119/1103) 10.4% (221/2123) 0.74
Bifurcation 9.7% (105/1085) 9.6% (198/2073) 0.91
Ostial lesion 14.4% (145/1009) 15.9% (296/1861) 0.28
No. of HBR criteria
Major ARC- HBR 0.7±0.6 0.6±0.6
Minor ARC- HBR 1.4±1.0 1.4±1.0
LEADERS FREE 1.4±0.6 1.3±0.6
Data are reported as percentage and number of patients as well as mean 
and SD as appropriate. ARC indicates Academic Research Consortium; HBR, 
high bleeding risk; LEADERS FREE, Prospective Randomized Comparison 
of the BioFreedom Biolimus A9 Drug- Coated Stent versus the Gazelle Bare- 
Metal Stent in Patients at High Bleeding Risk trial; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; and RVD, reference vessel diameter.
J Am Heart Assoc. 2020;9:e014611. DOI: 10.1161/JAHA.119.014611 5
Chandiramani et al Sex- Wise Differences in Patients at HBR Receiving PCI
non–ST- segment–elevation acute coronary syndrome 
presentations.
Predictors of 4- Year MB and MACE
Table 3 reports the independent predictors of MB and 
MACE (cardiac death, MI, or ST) at 4 years in women 
and men at HBR. The strongest predictors of MB were 
prior MI (HR, 1.75; P=0.02) in women at HBR, and mul-
tivessel disease (HR, 1.93; P=0.003) and age (HR, 1.03; 
P=0.02) in men at HBR. In regard to MACE, the strong-
est predictors for women at HBR were prior MI (HR, 
1.77; P=0.01) and diabetes mellitus (HR, 1.58; P=0.04), 
while for men at HBR they were multivessel disease 
(HR, 1.72; P=0.002), prior MI (HR, 1.67; P=0.003), and 
age (HR, 1.02; P=0.03).
Table S9 reports the bleeding risk (HR and 95% CI) 
associated with each major and minor ARC- HBR cri-
terion considered individually, when compared with the 
absence of any of these criteria (non- HBR group). Every 
criterion included in our adapted ARC- HBR definition 
was independently associated with an increased risk of 
MB compared with patients who were not at HBR.
DISCUSSION
The main findings of this large patient- level pooled 
analysis of 4 postapproval registries are as follows: 
(1) the prevalence of HBR was significantly higher in 
women compared with men; (2) clinical characteristics 
qualifying patients as HBR significantly differ between 
women and men at HBR; (3) at 4 years, women at HBR 
had significantly higher rates of MB compared with 
men at HBR; however, this difference was attenuated 
after adjustment for possible baseline confounders; (4) 
MACE rates between women and men at HBR were 
similar and remained consistent after multivariable 
adjustment.
Previous studies have shown significant differ-
ences between the risk profiles of women and men 
undergoing PCI, with women being older and having 
Figure 1. Comparison of the prevalence of various Academic Research Consortium High Bleeding Risk (ARC- HBR) criteria by sex.
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more associated comorbidities.16,17 Because of these 
factors, it was observed that women were at higher 
risk for both ischemic3,16,18 and bleeding events after 
PCI.2,19 Sex- related differences in pharmacodynamic 
and pharmacokinetic response to antithrombotic 
medications may partly explain the trend towards 
increased bleeding risk observed among women 
in clinical trials.20 Despite the continuous advance-
ments in DES technology and their association with 
improved outcomes compared with bare metal 
stents,7,8 physicians still tend to exercise caution 
when using DES for patients at HBR because of the 
alleged need for a longer duration of DAPT. This risk 
may be further amplified in women given their higher 
prevalence of HBR factors.
The HBR population constitutes a substantial por-
tion of patients undergoing PCI, with its prevalence 
varying based on definitions and inclusion criteria 
used for patient selection.21 We used the recently 
published consensus- based definition of the ARC 
consisting of major and minor criteria to identify our 
HBR population.13 Although the precise character-
ization of 20 clinical variables is primarily intended 
for prospective use in clinical trials, we adapted the 
definition according to the variables available in all of 
the included registries. In our analysis, we observed 
Figure 2. Sex- wise dual antiplatelet therapy (DAPT) management up to 4- year follow- up.
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that the prevalence of HBR in women was signifi-
cantly higher than in men (29.0% versus 20.5%, re-
spectively). This reflects the differences noted in the 
sex- wise HBR characteristics where we found that 
women at HBR had a higher prevalence of moder-
ate or severe anemia and CKD, 2 conditions that 
are often concomitant. Indeed, since erythropoietin 
production mainly takes place in the kidneys, it is 
hypothesized that a lack of this circulating factor is 
responsible for the occurrence of anemia in patients 
with CKD.22 Conversely, HBR- related conditions 
such as use of long- term oral anticoagulation, throm-
bocytopenia, and active malignancy were more fre-
quent in men at HBR. Finally, comorbidities such as 
diabetes mellitus, hypertension, and hyperlipidemia 
were more frequent in women at HBR, whereas men, 
although younger, were more likely to present with a 
history of prior MI and to be active smokers.
Importantly, we found that event rates for men and 
women at HBR were higher than both the patients 
not at HBR in our cohort as well as previously re-
ported all- comer contemporary PCI populations.23,24 
There are no prior data on sex- based long- term 
outcomes following PCI specifically in the HBR pop-
ulation with which the present results may be com-
pared. However, it has been previously reported in 
an all- comer population study that despite the more 
advanced age and greater prevalence of comorbid 
conditions, women undergoing PCI showed similar 
rates of mortality and ischemic outcomes as men.25 
We extend this evidence to the frail HBR population 
where we observed similar rates of MACE and its in-
dividual components between men and women at 
HBR; findings that remained consistent even after 
multivariable adjustment. Of note, the rates of MI and 
definite/probable ST in our study were lower com-
pared with those in the LEADERS FREE (Prospective 
Randomized Comparison of the BioFreedom 
Biolimus A9 Drug- Coated Stent versus the Gazelle 
Bare- Metal Stent in Patients at High Bleeding Risk) 
trial.7 This could be attributed to the differences in the 
prescribed DAPT duration, stent platforms, as well as 
complexity of coronary artery disease between the 
2 studies. While the protocol of the LEADERS FREE 
trial mandated only 1 month of DAPT after PCI, the 
registries included in our study had a longer DAPT 
Table 2. Sex- Wise 4- Year Outcomes in Patients at HBR 








(95% CI) P Value
Adjusted HR 
(95% CI) P Value
MACE 12.2% 12.6% 0.82 0.97 (0.75–1.25) 0.82 0.64 (0.32–1.28) 0.20
All- cause death 18.4% 18.4% 0.90 0.99 (0.80–1.21) 0.90 0.55 (0.30–1.03) 0.06
Cardiac death 9.7% 9.8% 0.88 0.98 (0.73–1.30) 0.88 0.52 (0.23–1.20) 0.13
Noncardiac death 9.7% 9.6% 0.98 1.00 (0.74–1.34) 0.98 0.63 (0.24–1.63) 0.34
MI 4.3% 3.9% 0.51 1.16 (0.75–1.80) 0.51 1.61 (0.55–4.72) 0.38
Definite/Probable ST 1.5% 2.0% 0.41 0.75 (0.37–1.50) 0.41 0.64 (0.10–3.93) 0.63
Major bleeding 10.8% 6.2% <0.0001 1.81 (1.34–2.43) <0.0001 0.92 (0.41–2.08) 0.84
ID- TLR 11.1% 7.4% 0.004 1.55 (1.16–2.08) 0.003 2.24 (1.07–4.68) 0.03
Adjusted hazard ratio (HR) adjusted for age 75 years and older, diabetes mellitus, smoker, hypertension, hyperlipidemia, prior myocardial infarction (MI), prior 
cardiac intervention, left ventricular ejection fraction <30%, acute coronary syndrome, multivessel disease, B2/C lesion. Major adverse cardiac event (MACE) 
is a composite of cardiac death, MI, or definite/probable stent thrombosis (ST). HBR indicates high bleeding risk; and ID- TLR, ischemia- driven target lesion 
revascularization.
Figure 3. Kaplan–Meier curves for 4- year clinical outcomes.
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duration. Contrary to the ischemic outcomes, we 
found that women at HBR experienced higher crude 
rates of MB compared with men at HBR. However, 
these differences were attenuated after adjusting 
for baseline clinical and procedural variables. This 
finding suggests that female sex, when considered 
in isolation, does not increase the risk for bleeding 
complications. It is rather the prevalence of specific 
clinical conditions associated with bleeding risk that 
vary according to sex, which determine the differ-
ence in outcomes between men and women. As 
such, women at HBR constitute a vulnerable subset 
of patients undergoing PCI and should therefore not 
be denied the benefits of coronary revascularization 
with DES implantation despite concerns regarding 
their worse baseline clinical characteristics.
At 4- year follow- up, the percentage of women 
at HBR on DAPT, although significantly lower than 
women not at HBR (38.7% versus 44.1%, respectively), 
was still much higher than expected. The high rates 
of DAPT prescription in women at HBR can be ex-
plained not only by the high prevalence of traditional 
risk factors such as diabetes mellitus but also by the 
fact that bleeding determinants such as CKD and 
prior stroke are also associated with ischemic risk,6 
which physicians tend to perceive and prioritize more 
compared with bleeding risk. Similarly, we observed 
that 37.3% of men at HBR were on DAPT at 4- year 
follow- up.
As patients at HBR tend to experience higher rates of 
both bleeding and ischemic events, we investigated the 
predictors of 4- year MB as well as MACE in patients at 
HBR according to sex. Notably, in women at HBR, prior 
MI was a strong predictor for both MB and MACE, while 
diabetes mellitus was an independent predictor only for 
MACE. These findings are concordant with what was 
observed in the PARIS (Patterns of Non- Adherence to 
Anti- Platelet Regimen in Stented Patients) study, which 
included both prior revascularization and diabetes mel-
litus in the risk score for coronary thrombotic events in 
the general population.6 For men at HBR, we found that 
multivessel disease and age were independent pre-
dictors for both MB and MACE, while prior MI was a 
strong predictor only for MACE. All of the above findings 
reinforce the need to not only consider the crucial fea-
tures specific to sex when approaching this frail patient 
population but to also customize the treatment modal-
ities and DAPT  duration according to the individual risk 
profile of each patient.
LIMITATIONS
As a post hoc analysis, the study findings should be 
considered exploratory. Since the current analysis was 
performed in a pooled data set exclusively evaluating 
the Xience V CoCr- EES, the findings cannot be extrap-
olated to other DES. Being a retrospective analysis of 
prospectively collected registries, unmeasurable con-
founders may have remained in spite of the multivari-
able adjustment. HBR was defined according to the 
recently published ARC- HBR criteria and adapted to 
the available data collected in the data set; however, 
we cannot exclude the possibility that the use of other 
HBR definitions could have altered the results. MI was 
defined according to the ARC definition in the Xience 
V China study and according to the WHO definition 
in the other registries, which may have potentially led 
to imprecision. Spontaneous bleeding requiring hos-
pitalization or transfusion and thrombocytopenia were 
not collected for the Xience V Japan and China regis-
tries, which may have led to an underestimation of the 
prevalence of HBR.
CONCLUSIONS
In this large patient- level pooled analysis of patients 
receiving CoCr- EES, the prevalence of HBR was sig-
nificantly higher in women compared with men. There 
were also important differences in the distribution of 
HBR characteristics according to sex. Women at 
Table 3. Sex- Wise Predictors of 4- Year MB and MACE
Variable
Coefficient 





Prior MI 0.56 (0.24) 1.75 (1.09–2.80) 0.02
Men at HBR
Multivessel disease 0.66 (0.22) 1.93 (1.26–2.95) 0.003
Age 0.03 (0.01) 1.03 (1.00–1.05) 0.02
MACE
Women at HBR
Prior MI 0.57 (0.23) 1.77 (1.13–2.77) 0.01
Diabetes mellitus 0.46 (0.22) 1.58 (1.02–2.45) 0.04
Men at HBR
Multivessel disease 0.54 (0.17) 1.72 (1.23–2.41) 0.002
Prior MI 0.51 (0.17) 1.67 (1.19–2.34) 0.003
Age 0.02 (0.01) 1.02 (1.00–1.04) 0.03
The multivariable model was created using stepwise regression, where 
variables were entered into the model either through clinical judgement or 
at the 0.05 significance level and removed at the 0.05 level (from the Wald 
chi- square statistic). Variables were eligible for inclusion in the multivariable 
model- building process if the variable was present for 90% of the patients in 
the analyses, had a univariate P<0.05, and had the higher level of significance 
if highly correlated with another variable (r>0.5 and P<0.05). Major bleeding 
(MB) was defined according to the Thrombolysis In Myocardial Infarction 
(TIMI) or Global Utilization of Streptokinase and TPA for Occluded arteries 
(GUSTO) scales depending on the registry, and included bleeding events 
categorized as TIMI minor/major (Xience V US and Xience V India) or GUSTO 
moderate/severe (Xience V China and Xience V Japan). Major adverse 
cardiac event (MACE) is a composite of cardiac death, myocardial infarction 
(MI), or definite/probable stent thrombosis. HBR indicates high bleeding risk; 
HR, hazard ratio; and SE, standard error.
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HBR experienced higher rates of MB but similar rates 
of MACE compared with men at HBR at 4 years.
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Table S1. List of adjudicated endpoints in included registries. 
XV Japan 
Stent thrombosis, cardiac death(s), suspected MI(s), and repeat TLR(s) and TVR(s) up to 3 
years.  
XV USA  
Death, MI, revascularization, and ST.  
Major bleeding complications will be adjudicated through 2-year follow-up.  
XV India 
ARC definitions for the following: death, MI, revascularization, and stent thrombosis.  
Major bleeding complications and unanticipated adverse device effects (UADEs) will 
also be adjudicated. 
XV China 
Stent thrombosis, cardiac death(s), suspected MI(s), and repeat revascularization. 
MI: myocardial infarction; TLR: target lesion revascularization; TVR: target vessel revascularization; ST: stent 
thrombosis; ARC: Academic Research Consortium. 
Table S2. Comparison of DAPT rates between male and female HBR patients. 
Time 
Female HBR 
(n = 821) 
Male HBR 
(n = 1,576) 
p-value 
1 year 75.4% 77.3% 0.30 
2 years 57.7% 57.7% >0.999 
3 years 49.0% 49.3% 0.88 
4 years 38.7% 37.3% 0.53 
DAPT: dual antiplatelet therapy; HBR: high bleeding risk. 
Table S3. Comparison of DAPT rates between male and female Non-HBR patients. 
Time 
Female Non-HBR 
(n = 2,011) 
Male Non-HBR 
(n = 6,094) 
p-value 
1 year 82.3% 85.0% 0.003 
2 years 58.4% 62.1% 0.003 
3 years 52.6% 54.8% 0.09 
4 years 44.1% 45.1% 0.46 
DAPT: dual antiplatelet therapy; HBR: high bleeding risk.  
Table S4. Sex-wise outcomes in HBR patients up to 3 years. 
 1 YEAR 2 YEARS 3 YEARS 
 
Female HBR  
(n = 821) 
Male HBR 
(n = 1,576) 
Female HBR  
(n = 821) 
Male HBR 
(n = 1,576) 
Female HBR  
(n = 821) 
Male HBR 
(n = 1,576) 
MACE 5.1% 4.7% 7.4% 7.9% 9.4% 9.8% 
All-cause death 4.6% 5.6% 9.7% 10.0% 12.8% 13.7% 
Cardiac death 3.0% 3.3% 5.3% 5.9% 7.0% 7.6% 
Non-cardiac death 1.7% 2.4% 4.7% 4.4% 6.2% 6.6% 
MI 2.6% 1.6% 3.0% 2.4% 3.5% 2.9% 
Definite/Probable ST 1.0% 1.2% 1.0% 1.3% 1.2% 1.5% 
Major bleeding 7.2% 3.9% 10.2% 5.5% 10.8% 5.8% 
ID-TLR 4.3% 3.4% 7.5% 5.0% 9.7% 6.1% 
MACE is a composite of cardiac death, MI or definite/probable ST. 
HBR: high bleeding risk; HR: hazard ratio; CI: confidence interval; MACE: major adverse cardiac events; MI: myocardial infarction; 
ST: stent thrombosis; ID-TLR: ischemia-driven target lesion revascularization. 
Table S5. Sex-wise and overall major bleeding rates in Non-HBR patients up to 4 years. 
 
Female Non-HBR 
(n = 2,011) 
Male Non-HBR 
(n = 6,094) 
Overall Non-HBR 
(n = 8,105) 
1 year 1.8% 1.5% 1.6% 
2 years 3.1% 2.0% 2.3% 
3 years 3.7% 2.5% 2.9% 
4 years 6.9% 4.6% 5.1% 
HBR: high bleeding risk  
Table S6. Sex-wise 4-year outcomes in the overall population. 
 
Female 
(n = 2,832) 
Male 









MACE 6.9% 6.0% 0.09 1.16 (0.98, 1.39) 0.09 0.90 (0.57, 1.43) 0.66 
All-cause death 8.6% 7.5% 0.09 1.14 (0.98, 1.34) 0.09 0.66 (0.42, 1.03) 0.07 
Cardiac death 4.0% 3.7% 0.47 1.09 (0.87, 1.37) 0.47 0.54 (0.27, 1.07) 0.08 
Non-cardiac death 4.8% 4.0% 0.10 1.20 (0.97, 1.48) 0.10 0.82 (0.44, 1.52) 0.53 
MI 3.5% 2.6% 0.02 1.36 (1.06, 1.75) 0.02 1.88 (1.03, 3.42) 0.04 
Definite/Probable ST 0.9% 0.9% 0.90 1.03 (0.64, 1.65) 0.90 0.91 (0.28, 2.93) 0.87 
Major bleeding 5.5% 3.0% <0.0001 1.85 (1.51, 2.28) <0.0001 0.91 (0.51, 1.64) 0.76 
ID-TLR 7.6% 5.9% 0.002 1.31 (1.10, 1.55) 0.002 1.44 (0.97, 2.16) 0.07 
Adjusted hazard ratio adjusted for age 75 years, diabetes mellitus, smoker, hypertension, hyperlipidemia, prior MI, prior cardiac intervention, 
LVEF <30%, acute coronary syndrome, multivessel disease, B2/C lesion.  
MACE is a composite of cardiac death, MI or definite/probable ST. HBR: high bleeding risk; HR: hazard ratio; CI: confidence interval; 
MACE: major adverse cardiac events; MI: myocardial infarction; ST: stent thrombosis; ID-TLR: ischemia-driven target lesion 
revascularization.  
Table S7. Sex-wise 4-year outcomes in HBR patients presenting with STEMI. 
 
Female HBR  
(n = 821) 
Male HBR 
(n = 1,576) 
HR (95% CI) p-value 
MACE 8.2% 11.3% 0.78 (0.22, 2.74) 0.70 
All-cause death 17.8% 15.6% 1.19 (0.47, 3.02) 0.71 
Cardiac death 8.2% 10.5% 0.86 (0.24, 3.04) 0.81 
Non-cardiac death 10.5% 5.8% 1.96 (0.47, 8.19) 0.35 
MI 2.9% 1.8% 1.66 (0.15, 18.35) 0.67 
Definite/Probable ST 2.6% 0.8% 3.21 (0.20, 51.29) 0.38 
Major bleeding 5.1% 3.4% 1.70 (0.31, 9.29) 0.54 
MACE is a composite of cardiac death, MI or definite/probable ST. HBR: high bleeding risk; HR: hazard ratio; CI: 
confidence interval; MACE: major adverse cardiac events; STEMI: ST-elevation myocardial infarction; ST: stent 
thrombosis. 
Table S8. Sex-wise 4-year outcomes in HBR patients presenting with NSTEACS. 
 
Female HBR  
(n = 821) 
Male HBR 
(n = 1,576) 
HR (95% CI) p-value 
MACE 12.7% 14.7% 0.88 (0.58, 1.34) 0.54 
All-cause death 19.6% 17.8% 1.11 (0.78, 1.58) 0.55 
Cardiac death 10.4% 10.1% 1.03 (0.64, 1.67) 0.90 
Non-cardiac death 10.2% 8.5% 1.22 (0.72, 2.04) 0.46 
MI 4.3% 4.1% 1.16 (0.55, 2.44) 0.69 
Definite/Probable ST 1.2% 3.0% 0.42 (0.12, 1.47) 0.16 
Major bleeding 13.2% 7.6% 1.79 (1.12, 2.86) 0.01 
MACE is a composite of cardiac death, MI or definite/probable ST. HBR: high bleeding risk; HR: hazard ratio; CI: 
confidence interval; MACE: major adverse cardiac events; NSTEACS: Non-ST elevation acute coronary syndrome; 
ST: stent thrombosis.  
Table S9. Bleeding risk of individual major and minor ARC-HBR criteria. 
ARC-HBR criterion HR (95% CI) p-value 
Major   
Moderate or severe anemia 6.69 (4.91, 9.13) <0.0001 
Oral anticoagulation 3.67 (2.53, 5.34) <0.0001 
Severe or end-stage CKD 6.02 (3.73, 9.71) <0.0001 
Thrombocytopenia 3.54 (1.44, 8.69) 0.003 
Prior spontaneous severe bleeding 11.39 (5.00, 25.92) <0.0001 
Active malignancy 5.53 (0.77, 39.66) 0.06 
Minor   
Age ≥75 years 3.83 (2.96, 4.95) <0.0001 
Mild anemia 3.16 (2.38, 4.21) <0.0001 
Moderate CKD 3.90 (2.97, 5.11) <0.0001 
Prior moderate or severe stroke 3.26 (2.17, 4.88) <0.0001 
ARC: Academic Research Consortium; HBR: high bleeding risk; CKD: chronic kidney disease; HR: hazard 
ratio; CI: confidence interval 
 
